Norway. 2 January 2019. Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Mark Wright as Head of Manufacturing.


.....Marco Renoldi, Nordic Nanovector’s Chief Operating Officer, said, “Mark has highly relevant experience in the manufacture of novel targeted therapeutics for cancer. We are pleased to welcome Mark to the team and anticipate that his expertise will prove highly valuable towards this goal. Dr Wright joins from Piramal Healthcare, an international Contract Development and Manufacturing Organisation.........


Ryddegutten tok styringen etter en uke ?. Fjernet en "hvilestudie" Lymrit 37 / 02 ( som nå er avsluttet historie) og oppjusterer / utvider en annen Lymrit 37 / 05

Lymrit 37 / 02

https://clinicaltrials.gov/ct2/history/NCT02657447?A=1&B=6&C=Side-by-Side#StudyPageTop


Lymrit 37 / 05

https://clinicaltrials.gov/ct2/history/NCT02658968?A=1&B=6&C=Side-by-Side#StudyPageTop


Så ble ARCHER 1 også oppdatert i WHO databasen 7 januar
.......................


Så er Lymrit 37 /07 inlagt i databasen til Clinical.gov 16 Januar

https://clinicaltrials.gov/ct2/show/NCT03806179


Så blir nok Lymrit 37 /01 oppdatert etter 27 februar 2019